• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The journal of clinical psychiatry >A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.
【24h】

A double-blind, placebo-controlled trial of extract of Ginkgo biloba added to haloperidol in treatment-resistant patients with schizophrenia.

机译：在氟哌啶醇中添加银杏叶提取物的双盲，安慰剂对照试验，用于治疗困难的​​精神分裂症患者。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

BACKGROUND: Many studies have indicated that excess free radical formation may be involved in the pathogenesis of patients with schizophrenia. Some investigators suggested that the use of free radical scavengers might provide improvement in schizophrenia. The aim of this study was to determine the effectiveness and to evaluate the side effects of extract of Ginkgo biloba (EGb) plus haloperidol in chronic, treatment-resistant inpatients with schizophrenia. METHOD: One hundred nine patients meeting DSM-III-R criteria for schizophrenia completed a double-blind, placebo-controlled, parallel-group study of EGb plus haloperidol. Fifty-six of the patients were randomly assigned to receive a fixed dose of 360 mg/day of EGb plus a stable dose of haloperidol, 0.25 mg/kg/day, and 53 were assigned to receive placebo plus the same dose of haloperidol for 12 weeks. Patients were assessed using the Brief Psychiatric Rating Scale (BPRS), the Scale for the Assessment of Negative Symptoms (SANS), and the Scale for the Assessment of Positive Symptoms (SAPS) at baseline, week 6, and week 12 and the Treatment Emergent Symptom Scale (TESS) for side effects at week 12. RESULTS: There was a significant reduction in both groups in BPRS total score after 12 weeks of treatment (p < .05). However, a significant reduction in total SAPS and SANS scores was noted in the EGb group (p < .05), but not in the placebo group. There was a lower SAPS total score in the EGb group than in the placebo group at the end of 12 weeks of treatment (p < .05). Of those treated with EGb plus haloperidol, 57.1% were rated as responders as compared with only 37.7% of those receiving placebo plus haloperidol when assessed by the SAPS (chi2 = 4. 111, p = .043). After 12 weeks of treatment, TESS subscore 1 (behavioral toxicity) and subscore 3 (symptoms of nerve system) were significantly decreased in the EGb group compared with the placebo group (p < .05). CONCLUSION: EGb treatment may enhance the effectiveness of antipsychotic drugs and reduce their extrapyramidal side effects.
机译：背景：许多研究表明，过量的自由基形成可能与精神分裂症患者的发病机制有关。一些研究者建议，使用自由基清除剂可能会改善精神分裂症。这项研究的目的是确定银杏叶提取物（EGb）和氟哌啶醇在慢性，难治性精神分裂症住院患者中的有效性并评估其副作用。方法：符合DSM-III-R精神分裂症标准的109位患者完成了EGb加氟哌啶醇的双盲，安慰剂对照，平行组研究。五十六名患者被随机分配接受固定剂量的360毫克/天的EGb加上稳定剂量的氟哌啶醇，0.25毫克/千克/天，而53名患者被分配接受安慰剂加相同剂量的氟哌啶醇治疗12周。在基线，第6周和第12周时使用简短精神病评定量表（BPRS），阴性症状评估量表（SANS）和阳性症状评估量表（SAPS）对患者进行了评估，并且出现了紧急治疗在第12周出现症状的症状量表（TESS）。结果：治疗12周后，两组的BPRS总评分均显着降低（p <.05）。但是，在EGb组中，SAPS和SANS总得分显着降低（p <.05），而在安慰剂组中则没有。在治疗12周结束时，EGb组的SAPS总分低于安慰剂组（p <.05）。在接受SAPS评估的患者中，接受EGb加氟哌啶醇治疗的患者中57.1％被评为有反应者，而接受安慰剂加氟哌啶醇的患者中只有37.7％（chi2 =4。111，p = .043）。治疗12周后，与安慰剂组相比，EGb组的TESS评分1（行为毒性）和评分3（神经系统症状）明显降低（p <0.05）。结论：EGb治疗可增强抗精神病药的有效性并降低其锥体外系副作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号